Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) — Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Thomas Lynch Jr., M.D., to its Board of Directors.

Dr. Thomas J. Lynch, Jr. is president and director of Fred Hutchinson Cancer Center and holder of the Raisbeck Endowed Chair, and sets the strategic direction of the center, oversees center-wide initiatives, and represents the Fred Hutch’s interests to major partners and governmental bodies. Prior to his role at Fred Hutch, Dr. Lynch served as Chief Scientific Officer at Bristol-Myers Squibb. Prior to that he held several leadership and clinician roles as director of Yale Cancer Center, physician in chief at Smilow Cancer Hospital, and chief of hematology-oncology at Massachusetts General Hospital.

“Tom is a world-renowned scientist and oncologist. I am delighted to have Tom joining our board of directors at this important time in the company’s evolution as we continue to advance both FHD-609 and FHD-286 through clinical trials and progress other pipeline programs towards the clinic,” said Foghorn CEO Adrian Gottschalk. “Tom’s deep scientific knowledge and clinical experience will be invaluable in helping to guide the Company through its next stage of growth.”

Douglas Cole, M.D., Flagship Pioneering Managing Partner, Foghorn Co-Founder and Chairman of the Board, continued, “We are thrilled to welcome Tom to the Foghorn Board. He is widely recognized for his dedication to improving patients’ lives through his work as a clinician and academic and industry leader. He understands patients’ needs, the research enterprise, and drug development. Tom’s experiences and perspectives will contribute critical insights to Foghorn’s mission to help people with cancer and other serious diseases.”

“I am excited to be joining the board of Foghorn and I look forward to collaborating with the other board members and the Foghorn team during this important stage of Foghorn’s journey,” said Dr. Lynch.

About Foghorn Therapeutics

Foghorn^® Therapeutics Inc. is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the company, and follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” regarding the Company’s growth and its goal of becoming a fully-integrated biotech company. Forward-looking statements include statements regarding the Company’s clinical trials, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Contact:

Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com

Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
khellsvik@foghorntx.com

Michael Lampe, ScientPR (Media)
michael@scientpr.com

Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com